
News|Articles|December 13, 2012
FDA updates safety review for smoking-cessation drug
The smoking-cessation drug varenicline (Chantix, Pfizer) may increase the risk of cardiovascular adverse events, according to an updated safety review from FDA.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
New therapies on the way to lower Lp(a), a cardiovascular risk factor
4
Many inherited eye disease genes rarely cause vision loss, study found
5




















































